-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Calumet, Raises Price Target to $45

Benzinga·08/18/2026 11:27:19
Listen to the news
Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $40 to $45.